Navigation Links
Coronado Biosciences Reports Third Quarter 2011 Financial Results
Date:11/15/2011

Corporate presentationAbout Coronado BiosciencesCoronado Biosciences is engaged in the development of novel immunotherapy biologic agents.  The Company's two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors.  For more information, please visit www.coronadobiosciences.com.  

Forward-Looking StatementsThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Such statements include, but are not limited to, any statements relating to the Company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings.  We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any chang
'/>"/>

SOURCE Coronado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
2. Coronado Biosciences to Present at the Rodman & Renshaw Annual Global Investment Conference
3. Coronado Biosciences Files to Become a Public Reporting Company
4. Coronado Biosciences Closes $25.8M in Series C Financing
5. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
6. Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH
7. Signum Biosciences, Inc. Announces Collaborative Agreement with GlaxoSmithKline
8. Neurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results
10. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
11. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  A recently published ... Houston, Texas , demonstrates that 3D ... increasing cancer detection. The study, "Implementation ... Observational Study," was led by Stephen L. ... issue of the American Journal of Roentgenology ...
(Date:5/23/2013)... -- More than half of women diagnosed with early ... still have excellent outcomes. To educate women, Agendia, Inc. ... sources of online consumer information about breast cancer genomic ... recently diagnosed women with information sources, to help them ... "We anticipate these innovative social media campaigns will encourage ...
(Date:5/23/2013)... 2013  Every day, their baby stopped breathing, his collapsed ... April and Bryan Gionfriddo watched helplessly, ... "Quite a few doctors said he had a good ... April Gionfriddo , about her now 20-month-old son, Kaiba. ... we would take it and run with it." ...
Breaking Medicine Technology:First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4
... -- Gentech Pharmaceutical, announced today it will be front and ... giving away freebies to the Hollywood elite from their display ... as part of the giveaways as the official weight loss ... in the GBK Gift Lounge on January 13th and 14th ...
... 5, 2012 /PRNewswire-iReach/ -- FutureNet,s Ambulatory ... government,s "meaningful use" stamp of approval by earning ... 5.2 software capable of enabling ambulatory/outpatient providers to ... Reinvestment Act (ARRA). Tested and certified under the ...
Cached Medicine Technology:Golden Globe Awards Adds Gentech Pharmaceutical as New Participating Sponsor 2FutureNet Granted Certification for Cloud-based Ambulatory EHR 2FutureNet Granted Certification for Cloud-based Ambulatory EHR 3
(Date:5/23/2013)... 2013 Susquehanna Health is ... comprehensive babysitting training course for adolescents age 11 and ... Indianapolis pediatrician Dr. Patricia Keener after a colleague’s toddler ... adult sitter who didn’t know how to provide first ... with a medical basis that aims to reduce the ...
(Date:5/23/2013)... to its destruction inside a cell, a cancer-promoting ... thwart the development of tumor-suppressing microRNAs (miRNAs) before ... publication at Nature . , Under conditions ... epidermal growth factor receptor (EGFR) gums up the ... scientists at The University of Texas MD Anderson ...
(Date:5/23/2013)... used next generation genomic analysis to determine that some ... genetic origins, which may help in predicting cancer progression. ... Cancer Research . , "This is the first study ... adjacent Gleason patterns in the same tumor allowing us ... Cheville, M.D., Mayo Clinic pathologist and one of the ...
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New ... Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol , dedicated ... who are considering filing lawsuits. , The painkiller ... liver damage, according to a 2009 report from the ... communication,” the FDA warned consumers against using more than ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 Dr. ... her new charitable organization in Orange County, OCCares , ... in Orange County. The event details are as follows: ... Orangewood Academy Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 ... pop crossover music by Christian vocalists Charmaine & Jonathan Thulin. ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3
... 67-Year-Old Great-Grandmother & Geriatric Care Manager Marion Somers, PhD, Will Visit 15 ... ... Politicians, NEW YORK, Sept. 24 Leading ... today kicked off her second national bus tour this year to raise,awareness ...
... Campaign Supports Susan G. Komen for the Cure with its ... Auction this October, WHAT: Emmy Award-winning journalist and TV personality Cristina ... Project Pink Campaign. Munchkin, Inc. ... products -- is once again reminding women everywhere "Don,t Duck a ...
... YORK, Sept. 24 There is clear evidence,that ... added to U.S. water,supplies, present potential risks to ... (NRC) first-ever published review of the,fluoride/thyroid literature.(A) ... 2/3 of U.S.,public water supplies, ostensibly to reduce ...
... 2007 -- A new study reports important evidence ... diagnosed with schizophrenia. Schizophrenia is considered one ... disorders, which has three distinct facets, often referred ... reduced capacity for pleasure), and cognitive (impairments in ...
... methods significantly raise exam rate, study finds , MONDAY, ... doctors, offices can improve colorectal cancer screening rates, a ... most common kind of cancer and the third leading ... patients don,t experience any symptoms until the disease is ...
... Health Solutions, Inc.,("SXC" or the "Company") (NASDAQ: SXCI ... services, announces that Gordon S. Glenn,Chairman and Chief Executive ... Officer, will present at the 2007 UBS Global Life,Sciences ... SXC,s presentation,will take place on Tuesday, September 25, 2007 ...
Cached Medicine News:Health News:Elder Care Author Doctor Marion Launches Second National Tour to Raise Awareness About Aging & Elder Care Issues in America 2Health News:Cristina Saralegui Joins Celebrities Including Matthew McConaughey, Courteney Cox and Mariska Hargitay to Raise Money for Breast Cancer Research 2Health News:Fluoride Damages the Thyroid, Report Shows 2Health News:Potential new approach to treat cognitive impairments in schizophrenia 2Health News:Doctors' Office Outreach Boosts Colon Cancer Screening 2